And what are you doing about it, is you try to influence the environment. From our perspective, the whole pharma industry and ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total pay increase, according (PDF) to a securities filing.

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Pfizer's ROE doesn't look that attractive. We then compared the company's ROE to the broader industry and were disappointed to see that the ROE is lower than the industry average of 19%.

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

Pfizer, one of the world’s largest pharmaceutical companies, has announced that David Lepoittevin will be its new country manager for Belgium and Luxembourg.